These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1903098)

  • 1. Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers.
    Turgeon J; Funck-Brentano C; Gray HT; Pavlou HN; Prakash C; Blair IA; Roden DM
    Clin Pharmacol Ther; 1991 May; 49(5):488-96. PubMed ID: 1903098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
    Funck-Brentano C; Turgeon J; Woosley RL; Roden DM
    J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiological effects of encainide and its metabolites in normal canine Purkinje fibers and Purkinje fibers surviving infarction.
    Kinnaird AA; Man RY
    Can J Physiol Pharmacol; 1989 Jul; 67(7):751-6. PubMed ID: 2504469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias.
    Turgeon J; Pavlou HN; Wong W; Funck-Brentano C; Roden DM
    J Pharmacol Exp Ther; 1990 Nov; 255(2):642-9. PubMed ID: 2123007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of encainide and metabolites (MJ14030 and MJ9444) on canine cardiac Purkinje and ventricular fibers.
    Elharrar V; Zipes DP
    J Pharmacol Exp Ther; 1982 Feb; 220(2):440-7. PubMed ID: 6799644
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of diltiazem on the disposition of encainide and its active metabolites.
    Kazierad DJ; Lalonde RL; Hoon TJ; Mirvis DM; Bottorff MB
    Clin Pharmacol Ther; 1989 Dec; 46(6):668-73. PubMed ID: 2513160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiological effects of encainide (MJ9067) on canine subendocardial Purkinje fibers surviving infarction.
    King BW; Man RY
    J Cardiovasc Pharmacol; 1984; 6(4):547-54. PubMed ID: 6206306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiologic effects of encainide (MJ 9067) on canine Purkinje fibres.
    Gibson JK; Somani P; Bassett AL
    Eur J Pharmacol; 1978 Nov; 52(2):161-9. PubMed ID: 729630
    [No Abstract]   [Full Text] [Related]  

  • 9. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.
    Turgeon J; Evans WE; Relling MV; Wilkinson GR; Roden DM
    Br J Clin Pharmacol; 1991 Sep; 32(3):283-8. PubMed ID: 1685663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of genetic polymorphism on the metabolism and disposition of encainide in man.
    Wang T; Roden DM; Wolfenden HT; Woosley RL; Wood AJ; Wilkinson GR
    J Pharmacol Exp Ther; 1984 Mar; 228(3):605-11. PubMed ID: 6423808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiologic evaluation of encainide with use of monophasic action potential recording.
    Samuelsson RG; Harrison DC
    Am J Cardiol; 1981 Nov; 48(5):871-6. PubMed ID: 6795911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of encainide on the determinants of cardiac excitability in sheep Purkinje fibers.
    Arnsdorf MF; Schmidt GA; Sawicki GJ
    J Pharmacol Exp Ther; 1985 Jan; 232(1):40-8. PubMed ID: 3917508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental electrophysiology of encainide and its major metabolites on the Purkinje fiber action potential.
    Case CL; Hewett KW; Gillette PC
    Biol Neonate; 1994; 66(6):330-8. PubMed ID: 7727615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depression of maximum rate of depolarization of guinea-pig ventricular action potentials by metabolites of encainide.
    Hemsworth PD; Campbell TJ
    Br J Pharmacol; 1989 Jun; 97(2):619-25. PubMed ID: 2503225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of encainide and its two major metabolites on cardiac conduction.
    Dresel PE
    J Pharmacol Exp Ther; 1984 Jan; 228(1):180-6. PubMed ID: 6420542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
    Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM
    Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interactions of quinidine and propranolol with mexiletine, encainide, flecainide and tocainide].
    Halawa B
    Pol Tyg Lek; 1990 Mar 5-12; 45(10-11):222-4. PubMed ID: 2120685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encainide: a new and potent antiarrhythmic agent.
    Harrison DC; Winkle R; Sami M; Mason J
    Am Heart J; 1980 Dec; 100(6 Pt 2):1046-54. PubMed ID: 6778194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations.
    McAllister CB; Wolfenden HT; Aslanian WS; Woosley RL; Wilkinson GR
    Xenobiotica; 1986 May; 16(5):483-90. PubMed ID: 3090789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ethmozin on excitability in sheep Purkinje fibers: the balance among active and passive cellular properties which comprise the electrophysiologic matrix.
    Arnsdorf MF; Sawicki GJ
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1158-66. PubMed ID: 2495352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.